Trial record 1 of 1 for:    NCT00805129
Previous Study | Return to List | Next Study

Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00805129
Recruitment Status : Active, not recruiting
First Posted : December 9, 2008
Last Update Posted : January 3, 2018
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center